Compatible FDA/EMA-approved targeted therapies and anew therapeutic options in advanced, complex and recalcitrant cancers.
Enrollment in relevant clinical trials for potential drug therapies in cancer cases with no clear available options.
Unhelpful therapies - limiting side effects and undue costs.
The knowledge gained from the genetic testing is shared by trained professionals with those who are at an increased risk of developing heritable cancer. The consuleing addresses the concerns of patients, their famillies, and their health care providers; and enables informed decision making.